Cancer Res. 2009 Jun 15;69(12):4941-4. Epub 2009 Jun 9.

Bispecific T-cell engaging antibodies for cancer therapy.

Source

Micromet Inc., Bethesda, Maryland, USA. patrick.baeuerle@micromet-inc.com

Abstract

There is increasing evidence that T cells are able to control tumor growth and survival in cancer patients, both in early and late stages of the disease. However, tumor-specific T-cell responses are difficult to mount and sustain in cancer patients, and are limited by numerous immune escape mechanisms of tumor cells selected during immunoediting. An alternative approach to engage T cells for cancer therapy are antibodies, which are bispecific for a surface target antigen on cancer cells, and for CD3 on T cells. These are capable of connecting any kind of cytotoxic T cell to a cancer cell, independently of T-cell receptor specificity, costimulation, or peptide antigen presentation. Here, we review the principle of a new class of bispecific antibodies called BiTE (for "bispecific T-cell engager") antibodies. Recent results from clinical studies with a CD19/CD3-bispecific BiTE antibody suggest that this therapeutic paradigm is finally showing promise for treatment of both bulky and minimal residual disease.

PMID:: 19509221; [PubMed - indexed for MEDLINE]

Free full text

Publication Types, MeSH Terms, Substances

Publication Types

Review

MeSH Terms

Substances

Antibodies, Bispecific

LinkOut - more resources

Supplemental Content

Related citations

Review BiTE: Teaching antibodies to engage T-cells for cancer therapy. [Curr Opin Mol Ther. 2009]
Review BiTE: Teaching antibodies to engage T-cells for cancer therapy.
Baeuerle PA, Kufer P, Bargou R. Curr Opin Mol Ther. 2009 Feb; 11(1):22-30.
Review Bispecific antibodies for polyclonal T-cell engagement. [Curr Opin Mol Ther. 2003]
Review Bispecific antibodies for polyclonal T-cell engagement.
Baeuerle PA, Kufer P, Lutterbüse R. Curr Opin Mol Ther. 2003 Aug; 5(4):413-9.
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. [J Immunother. 2007]
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
Brischwein K, Parr L, Pflanz S, Volkland J, Lumsden J, Klinger M, Locher M, Hammond SA, Kiener P, Kufer P, et al. J Immunother. 2007 Nov-Dec; 30(8):798-807.
Immunotherapy with bispecific antibodies. [Verh K Acad Geneeskd Belg. 1995]
Immunotherapy with bispecific antibodies.
Thielemans KM. Verh K Acad Geneeskd Belg. 1995; 57(3):229-47; discussion 247-8.
Review BiTEs: bispecific antibody constructs with unique anti-tumor activity. [Drug Discov Today. 2005]
Review BiTEs: bispecific antibody constructs with unique anti-tumor activity.
Wolf E, Hofmeister R, Kufer P, Schlereth B, Baeuerle PA. Drug Discov Today. 2005 Sep 15; 10(18):1237-44.

See reviews... See all...

Cited by 6 PubMed Central articles

A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. [MAbs. 2011]
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens.
Moore GL, Bautista C, Pong E, Nguyen DH, Jacinto J, Eivazi A, Muchhal US, Karki S, Chu SY, Lazar GA. MAbs. 2011 Nov 1; 3(6):546-57. Epub 2011 Nov 1.
Rational engineering of antibody therapeutics targeting multiple oncogene pathways. [MAbs. 2011]
Rational engineering of antibody therapeutics targeting multiple oncogene pathways.
Fitzgerald J, Lugovskoy A. MAbs. 2011 May 1; 3(3):299-309. Epub 2011 May 1.
Review Beyond chemotherapy: new agents for targeted treatment of lymphoma. [Nat Rev Clin Oncol. 2011]
Review Beyond chemotherapy: new agents for targeted treatment of lymphoma.
Younes A. Nat Rev Clin Oncol. 2011 Feb; 8(2):85-96. Epub 2010 Dec 14.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Bispecific T-cell engaging antibodies for cancer therapy.
Bispecific T-cell engaging antibodies for cancer therapy.
Cancer Res. 2009 Jun 15 ;69(12):4941-4. Epub 2009 Jun 9 .

PubMed
Do antiarrhythmic drugs work? Some reflections on the implications of the Cardia...
Do antiarrhythmic drugs work? Some reflections on the implications of the Cardiac Arrhythmia Suppression Trial.
Clin Cardiol. 1990 Oct ;13(10):725-8.

PubMed
Patterns of neural activity associated with honest and dishonest moral decisions...
Patterns of neural activity associated with honest and dishonest moral decisions.
Proc Natl Acad Sci U S A. 2009 Jul 28 ;106(30):12506-11. Epub 2009 Jul 21 .

PubMed
Effects of 1.8 GHz radiofrequency field on DNA damage and expression of heat sho...
Effects of 1.8 GHz radiofrequency field on DNA damage and expression of heat shock protein 70 in human lens epithelial cells.
Mutat Res. 2006 Dec 1 ;602(1-2):135-42. Epub 2006 Oct 2 .

PubMed
In vitro assessment of clastogenicity of mobile-phone radiation (835 MHz) using ...
In vitro assessment of clastogenicity of mobile-phone radiation (835 MHz) using the alkaline comet assay and chromosomal aberration test.
Environ Toxicol. 2008 Jun ;23(3):319-27.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Display Settings:

Send to:

Bispecific T-cell engaging antibodies for cancer therapy.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Supplemental Content

Related citations

Cited by 6 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information